Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

REGN

Regeneron Pharmaceuticals, Inc

Nov 20 • 04:00PM ET

737.00

+34.25 4.87 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ IVV SPY VTV IBB XLV JEPI COWZ

Scroll to Statements

Index	NDX, S&P 500	P/E	17.64	EPS (ttm)	41.77	Insider Own	3.73%	Shs Outstand	103.50M	Perf Week	6.04%
Market Cap	77.46B	Forward P/E	17.11	EPS next Y	43.07	Insider Trans	-0.18%	Shs Float	101.18M	Perf Month	26.04%
Enterprise Value	71.71B	PEG	4.89	EPS next Q	10.61	Inst Own	85.35%	Short Float	2.76%	Perf Quarter	25.03%
Income	4.58B	P/S	5.44	EPS this Y	-5.31%	Inst Trans	-2.14%	Short Ratio	2.61	Perf Half Y	23.48%
Sales	14.25B	P/B	2.51	EPS next Y	-0.30%	ROA	11.80%	Short Interest	2.79M	Perf YTD	3.46%
Book/sh	294.00	P/C	9.17	EPS next 5Y	3.61%	ROE	15.19%	52W High	800.99 -7.99%	Perf Year	-3.28%
Cash/sh	80.40	P/FCF	18.35	EPS past 3/5Y	-18.94% 15.74%	ROIC	13.60%	52W Low	476.49 54.67%	Perf 3Y	1.13%
Dividend Est.	3.06 (0.42%)	EV/EBITDA	16.47	Sales past 3/5Y	-4.04% 16.71%	Gross Margin	81.71%	Volatility	3.42% 3.29%	Perf 5Y	30.11%
Dividend TTM	3.52 (0.48%)	EV/Sales	5.03	EPS Y/Y TTM	0.50%	Oper. Margin	26.88%	ATR (14)	23.10	Perf 10Y	33.39%
Dividend Ex-Date	Nov 20, 2025	Quick Ratio	3.33	Sales Y/Y TTM	2.89%	Profit Margin	32.13%	RSI (14)	74.25	Recom	1.83
Dividend Gr. 3/5Y	- -	Current Ratio	4.06	EPS Q/Q	18.05%	SMA20	11.13%	Beta	0.36	Target Price	761.67
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	0.90%	SMA50	20.55%	Rel Volume	2.13	Prev Close	702.75
Employees	15106	LT Debt/Eq	0.09	Earnings	Oct 28 BMO	SMA200	23.73%	Avg Volume	1.07M	Price	737.00
IPO	Apr 02, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.53% 4.51%	Trades		Volume	2,279,568	Change	4.87%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-25	Initiated	Scotiabank	Sector Perform	$650
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy	$890
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720

Show Previous Ratings

Today 01:36PM	Stocks to Watch Thursday: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
11:08AM	Stock Market Today: Nasdaq, S&P 500 Stage Modest Comeback After Post-Earnings Nvidia Decline (TheStreet)
09:19AM	REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD (Zacks)
07:25AM	Regenerons Eylea franchise boosted by pair of FDA approvals (Pharmaceutical Technology)
06:36AM	With new approvals, Regenerons higher-dose Eylea gets more competitive (BioPharma Dive)
04:10PM	Loading…
Nov-19-25 04:10PM	EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications (GlobeNewswire)
07:00AM	Libtayo (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation (GlobeNewswire)
Nov-18-25 04:45AM	Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds? (Insider Monkey)
Nov-17-25 04:22PM	Stock Market Today: Dow Skids, AI Play Dives As Peter Thiel Exits; Netflix Divvies Up Its Shares (Live Coverage) (Investor's Business Daily)
03:02PM	Stock Market Today: Dow Dips As Biotech Eyes Entry; Why Netflix Went From $1,100 To $111 (Live Coverage) (Investor's Business Daily)
Nov-14-25 04:02PM	Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail (Investor's Business Daily)
08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-13-25 09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs (GlobeNewswire)
05:15AM	Here Are the Top Growth Healthcare Stocks Every New Investor Should Know (Motley Fool)
07:49PM	Loading…
Nov-12-25 07:49PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
12:26PM	Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains (Zacks)
Nov-10-25 04:20PM	Merck's Heart Pill Slashes Cholesterol Levels in Test Patients (Barrons.com)
06:56AM	Dupixent set for ninth US approval after Phase III AFRS success (Clinical Trials Arena)
04:25AM	Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks (StockStory)
Nov-08-25 02:32PM	Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% (Investor's Business Daily)
10:46AM	Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet (GlobeNewswire)
Nov-07-25 05:09PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
08:00AM	Dupixent (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review (GlobeNewswire)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
Nov-04-25 11:31PM	Michael Burry Is Super-Bearish On Palantir With 5 Million Puts (Benzinga)
12:38AM	5 Revealing Analyst Questions From Regeneron's Q3 Earnings Call (StockStory)
Nov-03-25 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
07:58AM	2 Beaten-Down Stocks That Could Be About to Rally (Motley Fool)
09:33AM	Loading…
Oct-31-25 09:33AM	Sometimes the only winning move is not to play, says Michael Burry in bubble warning (MarketWatch)
08:37AM	AstraZenecas gMG drug fails to fend off rivals despite Phase III win (Clinical Trials Arena)
07:00AM	Dupixent (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award (GlobeNewswire)
Oct-30-25 07:14PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Oct-29-25 03:29PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
12:11PM	Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher? (Barrons.com)
08:49AM	FDA rejects Regenerons pre-filled Eylea HD syringes amid filling facility woes (Pharmaceutical Technology)
01:32AM	REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage (StockStory)
12:03AM	Market Wrap: Top Stock Movers- PayPal, Nokia, and Wayfair (TheStreet)
Oct-28-25 03:03PM	REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase (Zacks) +11.82%
12:11PM	Why Are Regeneron (REGN) Shares Soaring Today (StockStory)
12:10PM	Nvidia investing $1B in Nokia, Trump admin. inks nuclear deal (Yahoo Finance Video)
09:30AM	Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics (Zacks)
09:01AM	Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts (Investor's Business Daily)
07:58AM	Regeneron (NASDAQ:REGN) Surprises With Strong Q3 (StockStory)
07:40AM	Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
07:06AM	Regeneron earnings beat estimates amid strong anti-inflammatory drug demand (Investing.com)
06:40AM	Regeneron: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Regeneron Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Oct-26-25 11:13PM	Regeneron Earnings: What To Look For From REGN (StockStory)
07:25AM	European Medicines Agency Adopts a Positive Opinion on ?Regeneron's (REGN) Libtayo (Insider Monkey)
Oct-24-25 07:03PM	Analyst Report: Sanofi (Morningstar Research)
04:12PM	Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue (Investor's Business Daily)
03:19PM	Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week (The Wall Street Journal)
01:14PM	Long Leaf Partners Fund's Comment on Regeneron (REGN) (Insider Monkey)
10:01AM	Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline (Zacks)
09:56AM	REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? (Zacks)
02:55AM	Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance (The Wall Street Journal)
Oct-23-25 09:15AM	Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS (Zacks)
09:05AM	RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised (Zacks)
Oct-21-25 10:00AM	Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline (Zacks)
Oct-20-25 09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks)
Oct-17-25 04:21PM	The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. (Investor's Business Daily)
07:30AM	Libtayo (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation (GlobeNewswire)
Oct-16-25 02:54AM	REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised) (Zacks)
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
07:00AM	Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers (GlobeNewswire)
Oct-14-25 10:49AM	Regenerons Q3 2025 Earnings: What to Expect (Barchart)
10:00AM	2 Stocks Down 17% and 21% to Buy Right Now (Motley Fool)
Oct-13-25 10:02AM	REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Zacks)
09:44AM	Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge (Insider Monkey)
09:41AM	Stock Market Today: Dow Jumps 400 Points On Trump Tariff Comments; Broadcom, Nvidia, Tesla Rally (Live Coverage) (Investor's Business Daily)
Oct-12-25 10:18AM	DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss (GlobeNewswire)
06:18AM	Regeneron, with game-changing new data, to seek approval of hearing loss gene therapy (BioPharma Dive)
Oct-09-25 04:08PM	Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out (Investor's Business Daily)
09:15AM	Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo (Zacks)
07:23AM	Regeneron, needing a turnaround, gains new use for cancer drug (BioPharma Dive)
Oct-08-25 02:31PM	Libtayo (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation (GlobeNewswire)
Oct-07-25 11:49AM	11 Cheap Stocks for a Market That's Too Expensive (Barrons.com)
Oct-06-25 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-02-25 04:55PM	Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management (Insider Monkey)
09:45AM	Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough (Insider Monkey)
Oct-01-25 08:10PM	Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials (Insider Monkey) +6.70%
02:16AM	Regeneron's Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5 (Insider Monkey)
Sep-30-25 04:05PM	Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 (GlobeNewswire)
07:30AM	2 Beaten-Down Stocks to Buy and Hold for a Decade (Motley Fool)
Sep-29-25 02:53PM	Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease (Insider Monkey)
10:43AM	Here's Why Regeneron Pharmaceuticals (REGN) Fell in Q2 (Insider Monkey)
08:28AM	FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza (Zacks)
06:02AM	Regenerons Evkeeza gains FDA approval for young HoFH patients (Pharmaceutical Technology)
12:36AM	1 Healthcare Stock with Exciting Potential and 2 We Ignore (StockStory)
Sep-26-25 07:00AM	Evkeeza (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol (GlobeNewswire)
Sep-25-25 04:51PM	Why Regeneron (REGN) Shares Are Falling Today (StockStory)
Sep-24-25 01:57AM	Regeneron's Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide (Insider Monkey)
Sep-23-25 03:26PM	Why Regeneron (REGN) Stock Is Down Today (StockStory)
09:45AM	Stock Market Today: Dow Up Ahead Of Powell Speech; Nvidia At Buy Point (Live Coverage) (Investor's Business Daily)
07:11AM	US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall (Reuters)
Sep-22-25 12:03PM	SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU (Zacks)
09:35AM	Humana initiated, Paycom upgraded: Wall Street's top analyst calls (The Fly)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bassler Bonnie L	Director	Nov 20 '25	Proposed Sale	750.00	760	570,000		Nov 20 02:31 PM
Pitofsky Jason	VP Controller	Nov 07 '25	Sale	651.43	431	280,766	4,233	Nov 10 04:37 PM
Jason Pitofsky	Officer	Nov 07 '25	Proposed Sale	651.00	431	280,581		Nov 07 05:06 PM
POON CHRISTINE A	Director	Oct 29 '25	Option Exercise	520.01	6,500	3,380,065	8,852	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 30 '25	Option Exercise	520.01	2,712	1,410,267	5,064	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 29 '25	Sale	654.27	6,500	4,252,745	2,352	Oct 31 04:09 PM
MURPHY ANDREW J	EVP Research	Oct 29 '25	Option Exercise	555.67	35,000	19,448,450	84,074	Oct 31 04:06 PM
Christine Poon	Director	Oct 29 '25	Proposed Sale	652.91	6,500	4,243,915		Oct 29 04:36 PM
SING GEORGE L	Director	Dec 31 '24	Option Exercise	413.33	3,338	1,379,696	29,610	Jan 03 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience